Evidence map›Paper›PMID 26019226›Full record

ArticleStem cells translational medicine2015

Allogeneic Neural Stem/Progenitor Cells Derived From Embryonic Stem Cells Promote Functional Recovery After Transplantation Into Injured Spinal Cord of Nonhuman Primates.

Hiroki Iwai, Hiroko Shimada, Soraya Nishimura, Yoshiomi Kobayashi, Go Itakura, Keiko Hori, Keigo Hikishima, Hayao Ebise, Naoko Negishi, Shinsuke Shibata and 4 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 72 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Hiroki IwaiDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Hiroko ShimadaDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Soraya NishimuraDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Yoshiomi KobayashiDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Go ItakuraDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Keiko HoriDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Keigo HikishimaDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Hayao EbiseDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Naoko NegishiDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Shinsuke ShibataDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Sonoko HabuDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Yoshiaki ToyamaDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan.
Masaya NakamuraDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan hidokano@a2.keio.jp masa@a8.keio.jp.
Hideyuki OkanoDepartments of Orthopaedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan; Genomic Science Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Department of Immunology, Juntendo University, Tokyo, Japan hidokano@a2.keio.jp masa@a8.keio.jp.
Keio University · JPJuntendo University · JPSumitomo Dainippon Pharma (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelled: Previous studies have demonstrated that neural stem/progenitor cells (NS/PCs) promote functional recovery in rodent animal models of spinal cord injury (SCI). Because distinct differences exist in the neuroanatomy and immunological responses between rodents and primates, it is critical to determine the effectiveness and safety of allografted embryonic stem cell (ESC)-derived NS/PCs (ESC-NS/PCs) in a nonhuman primate SCI model. In the present study, common marmoset ESC-NS/PCs were grafted into the lesion epicenter 14 days after contusive SCI in adult marmosets (transplantation group). In the control group, phosphate-buffered saline was injected instead of cells. In the presence of a low-dose of tacrolimus, several grafted cells survived without tumorigenicity and differentiated into neurons, astrocytes, or oligodendrocytes. Significant differences were found in the transverse areas of luxol fast blue-positive myelin sheaths, neurofilament-positive axons, corticospinal tract fibers, and platelet endothelial cell adhesion molecule-1-positive vessels at the lesion epicenter between the transplantation and control groups. Immunoelectron microscopic examination demonstrated that the grafted ESC-NS/PC-derived oligodendrocytes contributed to the remyelination of demyelinated axons. In addition, some grafted neurons formed synaptic connections with host cells, and some transplanted neurons were myelinated by host cells. Eventually, motor functional recovery significantly improved in the transplantation group compared with the control group. In addition, a mixed lymphocyte reaction assay indicated that ESC-NS/PCs modulated the allogeneic immune rejection. Taken together, our results indicate that allogeneic transplantation of ESC-NS/PCs from a nonhuman primate promoted functional recovery after SCI without tumorigenicity. SIGNIFICANCE: This study demonstrates that allogeneic embryonic stem cell (ESC)-derived neural stem/progenitor cells (NS/PCs) promoted functional recovery after transplantation into the injured spinal cord in nonhuman primates. ESC-NS/PCs were chosen because ESC-NS/PCs are one of the controls for induced pluripotent stem cell-derived NS/PCs and because ESC derivatives are possible candidates for clinical use. This translational research using an allograft model of a nonhuman primate is critical for clinical application of grafting NS/PCs derived from various allogeneic pluripotent stem cells, especially induced pluripotent stem cells, into injured spinal cord at the subacute phase.

Indexed as

AllograftCell transplantationEmbryonic stem cellsNeural stem cellsPrimatesSpinal cord injury

Identifiers

PMID26019226
PMCPMC4479619
OpenAlexW2162623914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.